Delivery Order SPE2DB24D8002-SPE2DB25FJNAW
Award Date
1/27/25
Potential Completion Date
1/28/25
Potential Value
$2.6K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,317.13, is for the delivery of the pharmaceutical product Fluticasone-Salmeterol 115-21 12GM. The contract has an ultimate completion date of February 25, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, valued at $999,999,999.00, as...
This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA). The $6,172.15 firm fixed-price delivery order contract is for the supply of Fluticasone-Salmeterol 230-21 12GM, a respiratory medication, to the DLA. This award is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a wide...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM, a pharmaceutical product, with a ceiling value of $9,035.88 and a period of performance through March 3, 2025. The contract is not set aside. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a $6,331.52 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM, a pharmaceutical product, with a performance period ending on January 15, 2025. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the ECAT Generation V Program, which allows the company to...
This contract award, valued at $1,524.99, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Fluticasone-Salmeterol 115-21 12GM, a pharmaceutical product. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and an ultimate completion date of February 13, 2025. Dakota Drug, Inc. holds a larger, single-award Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,830.16, is for the delivery of fluticasone-salmeterol 230-21 12GM pharmaceutical products to support U.S. Armed Forces medical operations. The contract is part of the DLA Troop Support Medical's ECAT Generation V Program, a larger indefinite delivery contract (IDC) vehicle with a ceiling value of...
This is a $5,346.71 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM pharmaceutical products to support U.S. Armed Forces medical operations. The contract is part of the DLA Troop Support Medical's ECAT Generation V Program, which allows Dakota Drug, Inc. to provide a comprehensive range of pharmaceutical products,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business that specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government. The contract, valued at $7,225.70, is a firm fixed-price delivery order for the supply of Fluticasone-Salmeterol 115-21 12GM inhalers. The award is associated with a larger Indefinite Delivery Contract (IDC) between Dakota...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,285.48 firm fixed-price contract is for the delivery of 4563652204 FLUTICASONE-SALMETEROL 230-21 12GM, a pharmaceutical product. The award is under the DLA Troop Support Medical's ECAT Generation V Program, a $999,999,999.00 Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc. This contract allows the company to provide a wide range...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,437.20 firm fixed-price delivery order contract is for the supply of Fluticasone-Salmeterol 115-21 12GM, a pharmaceutical product. The contract has an ultimate completion date of June 3, 2024. Dakota Drug, Inc. is an established vendor in the federal medical supply market, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...